We did a double-blind, randomised, phase 3 trial of the R21/Matrix-M malaria vaccine across five sites in four African countries with differing malaria transmission intensities and seasonality.

Email notifications are only sent once a day, and only if there are new matching items. The handful of women holding court Thursday around a table in Shawna Gonzales’ living room were animated by deep ...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Pfizer, NYSE:PFE, has entered a global licensing agreement ...

Editor’s note: The Tuesday and Wednesday, Jan. 27 and 28, performances at the Fisher Theatre have been canceled due to weather-related travel delays. Those wishing to exchange their tickets for ...

Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to use its Matrix-M adjuvant in vaccine products for up to two infectious ...

Per the terms of the agreement, Novavax will receive an upfront payment of $30 million from Pfizer and is eligible to earn up to $500 million in potential development and commercial milestone payments ...

Novavax secures a non-exclusive licensing deal with Pfizer, validating Matrix-M's platform value and shifting NVAX toward a technology provider model. NVAX receives $30M upfront, a potential $500M in ...

Novavax NVAX announced a non-exclusive license agreement with Pfizer PFE, granting the latter access to its proprietary Matrix-M adjuvant technology for use in up to two disease areas. The ...